Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	1.18T
Revenue (ttm)	1.20T
Net Income (ttm)	-116.55B
Shares Out	75.96M
EPS (ttm)	-1,880.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	586,178
Average Volume	648,713
Open	15,560
Previous Close	15,640
Day's Range	15,050 - 15,710
52-Week Range	9,260 - 16,020
Beta	0.38
RSI	71.83
Earnings Date	Nov 13, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.